Study of Intraperitoneal Carboplatin with IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

February 19, 2025 updated by: David O'Malley

Phase I Study of Intraperitoneal Carboplatin with Intravenous Paclitaxel and Bevacizumab in Patients with Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma

Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Phase I study with the primary objective to determine the maximum tolerated dose of intraperitoneal carboplatin and intravenous weekly paclitaxel given in combination with intravenous bevacizumab during the second two cycles of treatment in patients with chemo-naive epithelial ovarian, primary peritoneal or fallopian tube cancer. The maximum tolerated dose is defined as the highest dose at which no more than 1 of 6 evaluable patients experiences a dose limiting toxicity during the second two cycles of treatment. Secondary objectives are to determine response rates and to estimate progression free survival and overall survival of this class of patients.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Hilliard, Ohio, United States, 43026
        • OSU Gyn Oncology at Mill Run

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(Stage II, III or IV)either optimal or suboptimal after initial surgery.

    • All patients must have had appropriate surgery for ovarian, peritoneal, or fallopian tube carcinoma with tissue available for histologic evaluation
    • Histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant brenner tumor, adenocarcinoma NOS.
  • GOG(Gynecologic Oncology Group)performance status of 0,1,2
  • Entered within 12 weeks of most recent surgery performed for diagnosis.
  • Patients must have adequate bone marrow function, renal function,hepatic function, neurologic function, blood coagulation parameters within normal limits
  • Sign approved consent form.

Exclusion Criteria:

  • Patients who have received prior treatment other than initial surgery
  • Patients who have received prior radiotherapy to any portion of their abdominal cavity or pelvis
  • Patients with acute hepatitis or active infection
  • Patients with active bleeding
  • Patients with unstable angina
  • Patients with history of invasive malignancies with the exception of nonmelanoma skin cancer and localized breast cancer.
  • Patients who have received any target therapy or hormonal therapy for management of their ovarian cancer.
  • Patients with synchronous primary endometrial cancer.
  • Patients with epithelial tumors of low malignant potential
  • Serious non healing wound, ulcer or bone fracture.
  • Patients with history or evidence of CNS(central nervous system disease)
  • Patients under 18 years old.
  • Patients who have received prior therapy with anti-VEGF(vascular endothelial growth factor)

drug, bevacizumab

  • Patients who have a history of allergic reaction to polysorbate 80.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Carboplatin Paclitaxel & Bevacizumab
Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
Drug: Paclitaxel
Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
Other Names:
  • Taxol
  • Abraxane
Drug: Carboplatin
Intraperitoneal Day 1 cycles 1-6 AUC
Other Names:
  • Paraplatin®
Drug: Bevacizumab
Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
Other Names:
  • Avastin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Tolerated Dose
Time Frame: Every Cycle-28 days
The Maximum Tolerated Dose is defined as the highest dose at which no more than 1 of 6 evaluable patients experiences a dose limiting toxicity.
Every Cycle-28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response Rate, Progression Free Survival and Overall Survival
Time Frame: Every 3 monthes for 2 years, Every 6 months for 3 years.

Response Rate in patients with measurable disease using the RECIST(Response Evaluation Criteria in Solid Tumors)criteria.

Progression free survival is also uses the RECIST criteria or GCIG criteria. Overall survival will be followed for 5 years.
Every 3 monthes for 2 years, Every 6 months for 3 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

David O'Malley

Collaborators

Genentech, Inc.

Investigators

  • Principal Investigator: David O'Malley, MD, Ohio State University Comprehensive Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 28, 2011

Primary Completion (Actual)

July 17, 2023

Study Completion (Actual)

July 17, 2023

Study Registration Dates

First Submitted

October 12, 2010

First Submitted That Met QC Criteria

October 12, 2010

First Posted (Estimated)

October 13, 2010

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 19, 2025

Last Verified

December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OSU-09115
  • NCI-2012-00341 (Registry Identifier: Clinical Trials Reporting Program (CTRP))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe